These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16103498)

  • 1. Patient demand and politics push Herceptin forward.
    Kondro W; Sibbald B
    CMAJ; 2005 Aug; 173(4):347-8. PubMed ID: 16103498
    [No Abstract]   [Full Text] [Related]  

  • 2. PHARMAC responds on Herceptin assumptions and decisions.
    Metcalfe S; Evans J
    N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the ideal HER2 test for Herceptin therapy?
    Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
    [No Abstract]   [Full Text] [Related]  

  • 4. [Herceptin].
    Morginstin T; Shani S; Shemer J
    Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
    [No Abstract]   [Full Text] [Related]  

  • 6. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
    Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
    [No Abstract]   [Full Text] [Related]  

  • 7. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 8. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer.
    Smith M
    J Natl Cancer Inst; 2005 Sep; 97(18):1327. PubMed ID: 16174852
    [No Abstract]   [Full Text] [Related]  

  • 10. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 11. Isolated tumor cells in breast cancer.
    Sonke GS; Linn SC
    N Engl J Med; 2009 Nov; 361(20):1995; author reply 1995-6. PubMed ID: 19911470
    [No Abstract]   [Full Text] [Related]  

  • 12. [Herceptin therapy in breast cancer: new indication?].
    Lebeau A
    Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction. Herceptin: HER2 status--changing clinical practice.
    Piccart M; Kaufmann M
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S1-2. PubMed ID: 11167084
    [No Abstract]   [Full Text] [Related]  

  • 14. Herceptin.
    Peyrot J
    Oncol Nurs Forum; 1999 Apr; 26(3):515-6. PubMed ID: 10214591
    [No Abstract]   [Full Text] [Related]  

  • 15. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
    Burstein HJ; Winer EP
    J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
    [No Abstract]   [Full Text] [Related]  

  • 16. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 17. [Herceptin (trastuzumab)].
    Yamashiro H; Toi M
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.
    Fox KF
    Br J Cancer; 2006 Nov; 95(10):1454. PubMed ID: 17060943
    [No Abstract]   [Full Text] [Related]  

  • 19. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
    Láng I; Hitre E
    Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
    Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.